MedTrace Logo

LRRK2 G2385R Leucocyte and Urine Biomarker Study

NCT04436848 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2020-06-18

No results posted yet for this study

Summary

Given the emerging evidence on LRRK2-related biomarkers, this project will focus on identifying leucocyte and urine biomarkers that are altered by the LRRK2 G2385R variant, and investigating the effects of LRRK2 kinase inhibitor (MLi-2) on these biomarkers, using immunoblotting and mass spectrometry.

Conditions

  • Parkinson Disease

Interventions

OTHER

This is a non-interventional study

This is a non-interventional study

Sponsors & Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • University of Dundee

    collaborator OTHER

  • Nextcea, Inc

    collaborator UNKNOWN

  • Max Planck Institute of Biochemistry

    collaborator UNKNOWN

  • University of Malaya

    lead OTHER

Principal Investigators

  • Ai Huey Tan, MD, FRCP · University of Malaya

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-12-31
Completion
2022-06-30

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04436848 on ClinicalTrials.gov